Crinetics Pharma ((CRNX)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Study Overview: Crinetics Pharmaceuticals is conducting a study titled ‘A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atumelnant in Adult Participants With Classic Congenital Adrenal Hyperplasia (Calm-CAH)’. The study aims to assess the safety and efficacy of Atumelnant in treating adults with classic congenital adrenal hyperplasia (CAH) due to 21-OHD, a condition that affects adrenal gland function.
Intervention/Treatment: The study tests Atumelnant, an experimental drug administered orally in tablet form once daily for 32 weeks. A matching placebo will be used for comparison.
Study Design: This Phase 3 study is interventional and randomized with a parallel assignment. It employs triple masking, meaning the participant, care provider, and investigator are unaware of the treatment allocation. The primary purpose is treatment-focused.
Study Timeline: The study is not yet recruiting as of the last update on August 29, 2025. It was first submitted on August 20, 2025. These dates are crucial for tracking the study’s progress and upcoming recruitment phases.
Market Implications: The initiation of this study could impact Crinetics Pharma’s stock performance positively, as successful trials may lead to new treatment options for CAH, a niche market. Investors should watch for updates, as positive results could enhance Crinetics’ market position against competitors in the endocrinology sector.
The study is ongoing, with further details available on the ClinicalTrials portal.